Taseko Mines Ltd T.TKO

Alternate Symbol(s): TGB

Metals & Mining Copper

Taseko Mines Limited is a Canada-based mining company. The Company is principally engaged in the production and sale of metals, as well as related activities, including mine permitting and development within the province of British Columbia, Canada and the State of Arizona, the United States. The Company’s principal property is the Gibraltar Mine, which is a copper-molybdenum mine that is located in south-central British Columbia. It also owns the Florence Copper, Yellowhead copper, New Prosperity and Aley properties. The Florence Copper property is located midway between Phoenix and Tucson near the community of Florence, Arizona. The Yellowhead Project is located in the Thompson-Nicola area of British Columbia, approximately 150 kilometers northeast of Kamloops near Vavenby. The New Prosperity Project is a gold-copper porphyry, which is located in British Columbia. The Aley Niobium Project is located in northern British Columbia, approximately 140 kilometers north of Mackenzie.

TSX:TKO - Post by User

Taseko Mines Ltd > Potential Multiple Announcements

<< Previous

Bullboard Posts

Next >>

Post by coppermineron Feb 04, 2021 2:43pm

161 Views

Post# 32472476

Potential Multiple Announcements

Could be a number of New Releases Feb10. Our Qtr4/20 is due. Usually on a Wednesday about the midweek of the second week of the month. The Con. Call is the following Thursday. That could be a big day for Taseko shareholders

Still sticking to the idea that the Florence involves Material Change to the existing Taseko Mines Company. Any news of receipt of the Final Injection Permit should be treated as massive news, and the stock should be halted from trading pending public announcement by Taseko. Say halt at 12:00 noon, release news and reinstate trading after market close that day.

Could easily be a $2.50 / $3.00 new SP the following morning.

The cm report

<< Previous

Bullboard Posts

Next >>

Revolutionizing medical imaging with nanocarbon-based contrast drugs